These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 30523459)
1. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Paranjpe R; John G; Trivedi M; Abughosh S Breast Cancer Res Treat; 2019 Apr; 174(2):297-305. PubMed ID: 30523459 [TBL] [Abstract][Full Text] [Related]
2. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors. Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816 [TBL] [Abstract][Full Text] [Related]
3. Oral Endocrine Therapy Nonadherence, Adverse Effects, Decisional Support, and Decisional Needs in Women With Breast Cancer. Milata JL; Otte JL; Carpenter JS Cancer Nurs; 2018; 41(1):E9-E18. PubMed ID: 27532743 [TBL] [Abstract][Full Text] [Related]
4. Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis. Clancy C; Lynch J; OConnor P; Dowling M Eur J Oncol Nurs; 2020 Feb; 44():101706. PubMed ID: 32007696 [TBL] [Abstract][Full Text] [Related]
5. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Bright EE; Petrie KJ; Partridge AH; Stanton AL Breast Cancer Res Treat; 2016 Jul; 158(2):243-51. PubMed ID: 27342455 [TBL] [Abstract][Full Text] [Related]
6. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978 [TBL] [Abstract][Full Text] [Related]
7. Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Hwang GS; Paranjpe R; Opsomer C; Lu K; Abajue U; Abughosh S; Zaghloul H; Trivedi MV Clin Breast Cancer; 2020 Dec; 20(6):520-526. PubMed ID: 32669209 [TBL] [Abstract][Full Text] [Related]
8. [The importance of adherence to oral therapies in the field of oncology: the example of breast cancer]. Huiart L; Bardou VJ; Giorgi R Bull Cancer; 2013 Oct; 100(10):1007-15. PubMed ID: 24113516 [TBL] [Abstract][Full Text] [Related]
9. Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors. Uslu Y; Kocatepe V; Sezgin DS; Uras C Support Care Cancer; 2023 Apr; 31(5):285. PubMed ID: 37079089 [TBL] [Abstract][Full Text] [Related]
10. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study. Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973 [TBL] [Abstract][Full Text] [Related]
11. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Stanton AL; Petrie KJ; Partridge AH Breast Cancer Res Treat; 2014 Jun; 145(2):525-34. PubMed ID: 24781972 [TBL] [Abstract][Full Text] [Related]
12. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760 [TBL] [Abstract][Full Text] [Related]
13. Behavioral Interventions to Enhance Adherence to Hormone Therapy in Breast Cancer Survivors: A Systematic Literature Review. Hurtado-de-Mendoza A; Cabling ML; Lobo T; Dash C; Sheppard VB Clin Breast Cancer; 2016 Aug; 16(4):247-255.e3. PubMed ID: 27133733 [TBL] [Abstract][Full Text] [Related]
14. Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. Van Liew JR; Christensen AJ; de Moor JS J Cancer Surviv; 2014 Sep; 8(3):521-31. PubMed ID: 24986227 [TBL] [Abstract][Full Text] [Related]
15. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors. Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979 [TBL] [Abstract][Full Text] [Related]
16. Nonadherence to tamoxifen in breast cancer survivors: A 12 month longitudinal analysis. Moon Z; Moss-Morris R; Hunter MS; Norton S; Hughes LD Health Psychol; 2019 Oct; 38(10):888-899. PubMed ID: 31343218 [TBL] [Abstract][Full Text] [Related]
17. Adherence rates and correlates in long-term hormonal therapy. Dunn J; Gotay C Vitam Horm; 2013; 93():353-75. PubMed ID: 23810015 [TBL] [Abstract][Full Text] [Related]
18. Adherence to endocrine therapy for breast cancer. Chlebowski RT; Geller ML Oncology; 2006; 71(1-2):1-9. PubMed ID: 17344666 [TBL] [Abstract][Full Text] [Related]
19. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors. Brier MJ; Chambless DL; Chen J; Mao JJ Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F; Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]